← brief for 2026-10-07 · Slowing decline

Kidney Outcomes With GLP-1 Receptor Agonists and Tirzepatide Versus Finerenone in Type 2 Diabetes and Chronic Kidney Disease: A Real-World Cohort Study.

Article C Peer reviewed Observational

Key takeaways

This large study compared two diabetes drugs for people with kidney disease. It looked at real-world data to see which drug better protects the kidneys. This is an observational study, so it shows a link, not proof of cause.

Who did this work

Sehtman-Shachar DR · Fishkin A · Leibowitz G · Mosenzon O · Schechter M · Aharon-Hananel G

Source

Article · PubMed, the drug frontier · 2026 Oct 7
https://pubmed.ncbi.nlm.nih.gov/42842950/